Biogen (BIIB) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.
Label: Net selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.Sale Lloyd Minor, Director sold 593 shares at $203.34 ($121K).
- Trade date
- Aug 3, 2026
- Disclosed to the SEC
- Aug 5, 2026
- Type
- Pre-planned sale, 10b5-1 (code S)
Read the original SEC filing ↗All BIIB insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
BIIB insider transactions (Form 4)
Open-market purchases and sales. 78 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 5SEC | Lloyd MinorDirector | Sell Plan | 5933,282 held (−15%) | $203.34 | $121K | +22.8% | — |
| Aug 5SEC | Lloyd MinorDirector | Sell Plan | 5932,689 held (−18%) | $200.96 | $119K | +24.2% | — |
| Feb 17SEC | Nicole MurphyHead Of Pharm Ops And TechFirst buy | Buy | 319,611 held (+0%) | $195.03 | $585 | +28.0% | — |
| Feb 10SEC | Priya SinghalHead Of Development | Sell Plan | 2,6608,043 held (−25%) | $199.83 | $532K | +25.0% | — |
| Feb 3SEC | Priya SinghalHead Of Development | Sell Plan | 7486,271 held (−11%) | $179.30 | $134K | +39.3% | — |
Similar past setups: not applicable. BIIB has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with BIIB in the Research Lab
BIIB has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Biogen insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 2 sold $905K of BIIB stock on the open market; P/E 107.7 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
BIIB insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $240K | 2 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | $585 | 1 | $666K | 2 |
Valuation, profit and volume
Source: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 Biogen insiders reported open-market purchases totaling $0, while 2 insiders reported sales totaling $905K. Among insiders with enough purchase history to measure, Menelas N. Pangalos (Director) has the highest Insider Score at 100. 4 of 4 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
BIIB earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Oct 28, 2026 | +10.2% | None | -1.2%S&P -0.0% | pending |
| Jul 29, 2026 | -1.6% | None | +1.1%S&P +0.1% | +5.1% |
| Jul 1, 2026 | +8.8% | None | +0.0%S&P -0.3% | -6.1% |
| Apr 29, 2026 | +4.0% | None | +3.2%S&P +1.0% | +3.6% |
| Apr 6, 2026 | -2.7% | None | -1.0%S&P +0.5% | +9.0% |
| Feb 6, 2026 | +7.4% | Sold $134K | +4.6%S&P +2.4% | -1.7% |
| Jan 14, 2026 | +0.8% | None | -5.5%S&P -0.2% | +16.6% |
| Oct 30, 2025 | +1.8% | None | +4.3%S&P -0.8% | +18.0% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
BIIB short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded BIIB
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Alan ArmstrongSenate | Bought $1,001 - $15,000 | Mar 27, 2026 | Jul 21, 2026 | +35.8% |
Insiders at Biogen
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Priya SinghalHead Of Development | — | $666K | Feb 10, 2026 | — | — |
| Lloyd MinorDirector | — | $240K | Aug 5, 2026 | — | — |
| Nicole MurphyHead Of Pharm Ops And Tech | $585 | — | Feb 17, 2026 | — | — |
| Jane GroganHead Of Research | — | — | Nov 2, 2026 | — | — |
| Sean GodboutChief Accounting Officer | — | — | Oct 5, 2026 | — | — |
| Maria C. FreireDirector | — | — | Jun 11, 2026 | — | — |
| Menelas N. PangalosDirector | — | — | Jun 11, 2026 | 1 of 1 | 100 |
| Monish D. PatolawalaDirector | — | — | Jun 11, 2026 | — | — |
| Susan LangerDirector | — | — | Jun 11, 2026 | — | — |
| Jesus B. MantasDirector | — | — | Jun 11, 2026 | 0 of 1 | — |
| Eric K. RowinskyDirector | — | — | Jun 11, 2026 | 0 of 1 | — |
| Stephen A. SherwinDirector | — | — | Jun 11, 2026 | — | — |
| William A. HawkinsDirector | — | — | Jun 11, 2026 | — | — |
| Adam KeeneyHead Of Corporate Development | — | — | May 5, 2026 | — | — |
| Christopher ViehbacherCEO, President | — | — | Feb 10, 2026 | — | — |
| Susan H. AlexanderGeneral Counsel | — | — | Feb 10, 2026 | — | — |
| Ginger GregoryEvp, Human Resources | — | — | Feb 10, 2026 | — | — |
| Robin KramerCFO | — | — | Feb 10, 2026 | — | — |
| Rachid IzzarHead Of Global Product Strat. | — | — | Feb 10, 2026 | — | — |
Board links: companies that share insiders with BIIB
Directors and executives who filed Form 4s for BIIB and another company in the last 12 months.
- ABSIAbsci Menelas N. Pangalos Director here · Director at ABSI · latest filing Jun 11, 2026
- ADMArcher Daniels Midland Monish D. Patolawala Director here · CFO, President at ADM · latest filing Aug 5, 2026
- AREAlexandria Real Estate Equities Maria C. Freire Director here · Director at ARE · latest filing Jun 11, 2026
- BRVEBraveheart Bio Christopher Viehbacher CEO, President here · Director at BRVE · latest filing Aug 7, 2026
- EXELExelixis Maria C. Freire Director here · Director at EXEL · latest filing Jun 11, 2026
- NBIXNeurocrine Biosciences Stephen A. Sherwin Director here · Director at NBIX · latest filing Jun 11, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
BIIB stock: common questions
Are Biogen insiders buying BIIB stock?
No. No Biogen insider reported an open-market purchase of BIIB in the past 12 months. The latest was Head Of Pharm Ops And Tech Nicole Murphy bought $585 of BIIB at $195.03 — first open-market purchase in our records.
Are Biogen insiders selling BIIB stock?
2 insiders reported sales worth $905K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is BIIB's P/E ratio?
BIIB trades at about 107.7 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is BIIB's 52-week range?
Over the past year BIIB has traded between $164.42 and $254.87. It last closed at $249.69 on Nov 20, 2026.